The role of metabolomics in neurological disease

Journal of Neuroimmunology

Volumn 248, Issue 1-2, 2012, Pages 48-52

  Hassan Smith, Ghaniah ^a   Wallace, Graham R ^a   Douglas, Michael R ^a,b   Sinclair, Alexandra J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Metabolomics; Multiple sclerosis; Neurology

Indexed keywords

AUTOIMMUNE DISEASE; BRAIN METABOLISM; DISEASE COURSE; HUMAN; HUNTINGTON CHOREA; MEDICAL DECISION MAKING; METABOLOMICS; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; NERVOUS SYSTEM DISEASES;

EID: 84862623984     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.01.009     Document Type: Review

References (37)

1. Aasly J., Gårseth M., Sonnewald U., Zwart J.A., White L.R., Unsgård G. Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis. Acta Neurol. Scand. 1997, 95:9-12.
2. Ahmed S.S., Santosh W., Kumar S., Christlet H.T. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 2009, 16:63.
3. 1H NMR- and MS-based metabonomic analysis. Epilepsy Res. 2010, 88:189-195.
4. 1H NMR-based metabonomic approach using vitreous humor. Investig. Ophthalmol. Vis. Sci. 2010, 51:4416-4421.
5. Barnes V.M., Ciancio S.G., Shibly O., Xu T., Devizio W., Trivedi H.M., Guo L., Jönsson T.J. Metabolomics reveals elevated macromolecular degradation in periodontal disease. J. Dent. Res. 2011.
6. Bernard-Hélary K., Ardourel M., Magistretti P., Hévor T., Cloix J.-F. Stable transfection of cDNAs targeting specific steps of glycogen metabolism supports the existence of active gluconeogenesis in mouse cultured astrocytes. Glia 2002, 37:379-382.
7. Bjartmar C., Battistuta J., Terada N., Dupree E., Trapp B.D. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann. Neurol. 2002, 51:51-58.
8. Bogdanov M., Matson W.R., Wang L., Matson T., Saunders-Pullman R., Bressman S.S., Beal M.F. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008, 131:389-396.
9. De Stefano N., Narayanan S., Francis G.S., Arnaoutelis R., Tartaglia M.C., Antel J.P., Matthews P.M., Arnold D.L. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch. Neurol. 2001, 58:65-70.
10. Fisniku L.K., Brex P.A., Altmann D.R., Miszkiel K.A., Benton C.E., Lanyon R., Thompson A.J., Miller D.H. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
11. Floegel A., Drogan D., Wang-Sattler R., Prehn C., Illig T., Adamski J., Joost H.-G., Boeing H., Pischon T. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS One 2011, 6:e21103.
12. Ghauri F.Y., Nicholson J.K., Sweatman B.C., Wood J., Beddell C.R., Lindon J.C., Cairns N.J. NMR spectroscopy of human post mortem cerebrospinal fluid: distinction of Alzheimer's disease from control using pattern recognition and statistics. NMR Biomed. 1993, 6:163-167.
13. Hassan-Smith G., Douglas M.R. Epidemiology and diagnosis of Multiple Sclerosis. Br. J. Hosp. Med. (Lond.) 2011, 72(10):M146-M151.
14. Hassan-Smith G., Douglas M.R. Management and prognosis of Multiple Sclerosis. Br. J. Hosp. Med. (Lond.) 2011, 72(11):M174-M176.
15. Inglese M., Li B.S.Y., Rusinek H., Babb J.S., Grossman R.I., Gonen O. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn. Reson. Med. 2003, 50:190-195.
16. Kumar A., Bala L., Kalita J., Misra U.K., Singh R.L., Khetrapal C.L., Babu G.N. Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin. Chim. Acta 2010, 411:563-567.
17. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J. Neurol. Sci. 2003, 206:187-191.
18. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J. Proteome Res. 2010, 9:4545-4553.
19. Lutz N.W., Viola A., Malikova I., Confort-Gouny S., Audoin B., Ranjeva J.-P., Pelletier J., Cozzone P.J. Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One 2007, 2:e595.
20. Lynch J., Peeling J., Auty A., Sutherland G.R. Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis. Can. J. Neurol. Sci. 1993, 20:194-198.
21. Madsen R.K., Lundstedt T., Gabrielsson J., Sennbro C.J., Alenius G.M., Moritz T., Rantapaa-Dahlqvist S., Trygg J. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res. Ther. 2011, 13:R19.
22. Mahad D., Lassmann H., Turnbull D. Review: mitochondria and disease progression in multiple sclerosis. Neuropathol. Appl. Neurobiol. 2008, 34:577-589.
23. Mishur R.J., Rea S.L. Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases. Mass Spectrom. Rev. 2012, 31(1):70-95.
24. Mochel F., Boildieu N., Barritault J., Sarret C., Eymard-Pierre E., Seguin F., Schiffmann R., Boespflug-Tanguy O. Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseases. Biochim. Biophys. Acta 2010, 1802:1112-1117.
25. Mochel F., Engelke U.F.H., Barritault J., Yang B., Mcneill N.H., Thompson J.N., Vanderver A., Wolf N.I., Willemsen M.A., Verheijen F.W., Seguin F., Wevers R.A., Schiffmann R. Elevated CSF N-acetylaspartylglutamate in patients with free sialic acid storage diseases. Neurology 2010, 74:302-305.
26. Nicoli F., Vion-Dury J., Confort-Gouny S., Maillet S., Gastaut J.L., Cozzone P.J. Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy. CR Acad. Sci. III 1996, 319:623-631.
27. Nicoli F., Vion-Dury J., Maloteaux J.M., Delwaide C., Confort-Gouny S., Sciaky M., Cozzone P.J. CSF and serum metabolic profile of patients with Huntington's chorea: a study by high resolution proton NMR spectroscopy and HPLC. Neurosci. Lett. 1993, 154:47-51.
28. Psychogios N., Hau D.D., Peng J., Guo A.C., Mandal R., Bouatra S., Sinelnikov I., Krishnamurthy R., Eisner R., Gautam B., Young N., Xia J., Knox C., Dong E., Huang P., Hollander Z., Pedersen T.L., Smith S.R., Bamforth F., Greiner R., McManus B., Newman J.W., Goodfriend T., Wishart D.S. The Human Serum Metabolome. PLoS One 2011, 6:e16957.
29. Rigotti D.J., Gonen O., Grossman R.I., Babb J.S., Falini A., Benedetti B., Filippi M. Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am. J. Neuroradiol. 2010, ajnr.A2254.
30. Simone I.L., Federico F., Trojano M., Tortorella C., Liguori M., Giannini P., Picciola E., Natile G., Livrea P. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J. Neurol. Sci. 1996, 144:182-190.
31. Sinclair A.J., Viant M.R., Ball A.K., Burdon M.A., Walker E.A., Stewart P.M., Rauz S., Young S.P. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases-a diagnostic tool?. NMR Biomed. 2009, 23:123-132.
32. Sinclair A.J., Viant M.R., Ball A.K., Burdon M.A., Walker E.A., Stewart P.M., Rauz S., Young S.P. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases-a diagnostic tool?. NMR Biomed. 2010, 23:123-132.
33. Suhre K., Shin S.-Y., Petersen A.-K., Mohney R.P., Meredith D., Wagele B., Altmaier E., Cardiogram, Deloukas P., Erdmann J., Grundberg E., Hammond C.J., De Angelis M.H., Kastenmuller G., Kottgen A., Kronenberg F., Mangino M., Meisinger C., Meitinger T., Mewes H.-W., Milburn M.V., Prehn C., Raffler J., Ried J.S., Romisch-Margl W., Samani N.J., Small K.S., Erich Wichmann H., Zhai G., Illig T., Spector T.D., Adamski J., Soranzo N., Gieger C. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011, 477:54-60.
34. Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P., McCabe E., Lewis G.D., Fox C.S., Jacques P.F., Fernandez C., O'Donnell C.J., Carr S.A., Mootha V.K., Florez J.C., Souza A., Melander O., Clish C.B., Gerszten R.E. Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011, 17:448-453.
35. Wolf N.I.M., Willemsen M.A.A.P.M.D.P., Engelke U.F., Van Der Knaap M.S.M.D.P., Pouwels P.J.W.P., Harting I.M., Zschocke J.M.D.P., Sistermans E.A.P., Rating D.M., Wevers R.A.P. Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF. Neurology 2004, 62:1503-1508.
36. Young S.P., Nessim M., Falciani F., Trevino V., Banerjee S.P., Scott R.A., Murray P.I., Wallace G.R. Metabolomic analysis of human vitreous humor differentiates ocular inflammatory disease. Mol. Vis. 2009, 15:1210-1217.
37. Zeinstra E., Wilczak N., De Keyser J. [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neurosci. Lett. 2000, 289:75-77.